Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation

Bibliography

• Elting LS, Cooksley C, Chambers M, The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-9
   PubMed Web of Science ®Google Scholar
• Bellm LA, Epstein JB, Rose-Ped A, Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9
   PubMed Web of Science ®Google Scholar
• Gabriel DA, Shea T, Olajida O, The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol 2003;30:76-83
   PubMed Web of Science ®Google Scholar
• Ruescher TJ, Sodeifi A, Scrivani SJ, The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998;82:2275-81
   PubMed Web of Science ®Google Scholar
• Sonis ST, Oster G, Fuchs H, Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-5
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007;68:1110-20
   PubMed Web of Science ®Google Scholar
• World Health Organization: WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva, Switzerland; 1979
   Google Scholar
• Sonis ST, Elting LS, Keefe D, Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995-2025
   PubMed Web of Science ®Google Scholar
• Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-17
   PubMed Web of Science ®Google Scholar
• Wang EH, Chen YA, Corringham S, High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004;34:581-7
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P, Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy – European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008;26:1519-25
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W, Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8
   PubMed Web of Science ®Google Scholar
• Schmidt E, Thoennissen NH, Rudat A, Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol 2008;19:1644-9
   PubMed Web of Science ®Google Scholar
• Rosen LS, Abdi E, Davis ID, Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-200
   PubMed Web of Science ®Google Scholar
• Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998;9:153-65
   PubMed Web of Science ®Google Scholar
• Robien K, Schubert MM, Bruemmer B, Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004;22:1268-75
   PubMed Web of Science ®Google Scholar
• Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009;45:1015-20
   PubMed Web of Science ®Google Scholar
• Blijlevens NM, Donnelly JP, DePauw BE. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005;36:703-7
   PubMed Web of Science ®Google Scholar
• Yeoh AS, Bowen JM, Gibson RJ, Keefe DM. Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005;63:1295-303
   PubMed Web of Science ®Google Scholar
• Stringer AM, Gibson RJ, Bowen JM, Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007;5:259-67
   PubMedGoogle Scholar
• Ong ZY, Gibson RJ, Bowen JM, Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010;5:22
   PubMed Web of Science ®Google Scholar
• Keefe DM, Schubert MM, Elting LS, Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-31
   PubMed Web of Science ®Google Scholar
• Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2006:CD000978
   Google Scholar
• Rubenstein EB, Peterson DE, Schubert M, Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-46
   PubMed Web of Science ®Google Scholar
• Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994;30B:234-6
   PubMed Web of Science ®Google Scholar
• Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy – a randomized controlled trial. Support Care Cancer 2007;15:1155-61
   PubMed Web of Science ®Google Scholar
• Svanberg A, Ohrn K, Birgegard G. Oral cryotherapy reduces mucositis and improves nutrition – a randomised controlled trial. J Clin Nurs 2010;19:2146-51
   PubMed Web of Science ®Google Scholar
• Lilleby K, Garcia P, Gooley T, A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:1031-5
   PubMed Web of Science ®Google Scholar
• Gori E, Arpinati M, Bonifazi F, Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 2007;39:347-52
   PubMed Web of Science ®Google Scholar
• Harris DJ, Eilers J, Harriman A, Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs 2008;12:141-52
   PubMed Web of Science ®Google Scholar
• Rubin JS, Osada H, Finch PW, Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989;86:802-6
   PubMed Web of Science ®Google Scholar
• Auf DU, Krampert M, Kumin A, Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Cell Biol 2004;83:607-12
   PubMed Web of Science ®Google Scholar
• Swedish Orphan Biovitrum. Product information (US): Kepivance (palifermin 6.25 mg) lyophilized powder for IV injection 2008 [online]. Available from: http://www.kepivance.com
   Google Scholar
• Geer DJ, Swartz DD, Andreadis ST. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am J Pathol 2005;167:1575-86
   PubMed Web of Science ®Google Scholar
• Farrell CL, Rex KL, Chen JN, The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 2002;35(Suppl 1):78-85
   PubMedGoogle Scholar
• Bao S, Wang Y, Sweeney P, Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288:L36-42
   PubMed Web of Science ®Google Scholar
• Wu KI, Pollack N, Panos RJ, Keratinocyte growth factor promotes alveolar epithelial cell DNA repair after H2O2 exposure. Am J Physiol 1998;275:L780-7
   PubMed Web of Science ®Google Scholar
• Braun S, Hanselmann C, Gassmann MG, Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002;22:5492-505
   PubMed Web of Science ®Google Scholar
• Zia-Amirhosseini P, Hurd DD, Salfi M, Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy 2007;27:1353-60
   PubMed Web of Science ®Google Scholar
• Gillespie B, Zia-Amirhosseini P, Salfi M, Effect of renal function on the pharmacokinetics of Palifermin. J Clin Pharmacol 2006;46:1460-8
   PubMed Web of Science ®Google Scholar
• Zia-Amirhosseini P, Salfi M, Leese P, Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 2006;79:558-69
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Somer RA, Gutheil J, Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003;21:1452-8
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Emanouilidis C, Efficacy of recombinant human keratinocyte growth factor in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral plod progenitor transplantation after radiation-based conditioning – results of a phase II study [abstract #25]. Proc Am Soc Clin Oncol 2001;30:3
   Google Scholar
• Bensinger W, Schubert M, Ang KK, NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008;6(Suppl 1):S1-21
   PubMedGoogle Scholar
• Elting LS, Shih YC, Stiff PJ, Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007;13:806-13
   PubMed Web of Science ®Google Scholar
• Krijanovski OI, Hill GR, Cooke KR, Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999;94:825-31
   PubMed Web of Science ®Google Scholar
• Blazar BR, Weisdorf DJ, Defor T, Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108:3216-22
   PubMed Web of Science ®Google Scholar
• Levine JE, Blazar BR, Defor T, Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 2008;14:1017-21
   PubMed Web of Science ®Google Scholar
• Langner S, Staber P, Schub N, Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008;42:275-9
   PubMed Web of Science ®Google Scholar
• Nasilowska-Adamska B, Rzepecki P, Manko J, The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007;40:983-8
   PubMed Web of Science ®Google Scholar
• Rzepecki P, Sarosiek T, Barzal J, Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation – single centre experience. J BUON 2007;12:477-82
   PubMed Web of Science ®Google Scholar
• Verhagen MP, Wondergem MJ, Visser O. Palifermin dose should be adjusted to different therapy regimens. Bone Marrow Transplant 2009;43:665
   PubMed Web of Science ®Google Scholar
• Kobbe G, Bruns I, Schroeder T, A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010;21:1898-904
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Trent J, Patel S, Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 2010;153:358-67
   PubMed Web of Science ®Google Scholar
• Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002;54:245-51
   PubMed Web of Science ®Google Scholar
• Dorr W, Bassler S, Reichel S, Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys 2005;62:881-7
   PubMed Web of Science ®Google Scholar
• Jaal J, Richter C, Dorr W. Effect of recombinant human keratinocyte growth factor (Δ23rHuKGF, Palifermin) on inflammatory and immune changes in mouse tongue during fractionated irradiation. Int J Radiat Biol 2010;86:860-6
   PubMed Web of Science ®Google Scholar
• Brizel DM, Murphy BA, Rosenthal DI, Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-96
   PubMed Web of Science ®Google Scholar
• Le Q, Kim H, Schneider C. Palifermin reduces severe oral mucositis in subjects with locally advanced head and neck cancer undergoing chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008;72:S32-3
   Web of Science ®Google Scholar
• Henke M, Alfonsi M, Foa P. Palifermin significantly reduces severe oral mucositis in subjects with resected locally advanced head and neck cancer undergoing post-operative concurrent radiochemotherapy. Radiother Oncol 2008;88(Suppl 2):S152
   Google Scholar
• Blijlevens N, de Chateau M, Krivan G. Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis in Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan. Blood (ASH Annual Meeting Abstracts) 2010;116:904
   Google Scholar
• Keijzer A, Huijgens PC, van de Loosdrecht AA. Palifermin and palmar-plantar erythrodysesthesia. Br J Haematol 2007;136:856-7
   Google Scholar
• Sibelt LA, Aboosy N, van der Velden WJ, Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases. Br J Dermatol 2008;159:1200-3
   Google Scholar
• Lee M, Grassi M. Acanthosis nigricans in a patient treated with palifermin. Cutis 2010;86:136-7
   Google Scholar
• Schroeder T, Zohren F, Saure C, Palifermin, a recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non-Hodgkin lymphoma. Bone Marrow Transplant 2009;44:823-4
   Google Scholar
• Lovicu FJ, Overbeek PA. Overlapping effects of different members of the FGF family on lens fiber differentiation in transgenic mice. Development 1998;125:3365-77
   PubMed Web of Science ®Google Scholar
• Finch PW, Rubin JS, Miki T, Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 1989;245:752-5
   PubMed Web of Science ®Google Scholar
• Siddiqi I, Funatomi H, Kobrin MS, Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1995;215:309-15
   PubMed Web of Science ®Google Scholar
• Tamaru N, Hishikawa Y, Ejima K, Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 2004;84:1460-71
   PubMed Web of Science ®Google Scholar
• Shin EY, Lee BH, Yang JH, Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol 2000;126:519-28
   PubMed Web of Science ®Google Scholar
• Ning S, Shui C, Khan WB, Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998;40:177-87
   PubMed Web of Science ®Google Scholar
• Hille A, Rave-Frank M, Pradier O, Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 2003;79:119-28
   PubMed Web of Science ®Google Scholar
• Hille A, Gruger S, Christiansen H, Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro. Radiat Environ Biophys 2010;49:261-70
   PubMed Web of Science ®Google Scholar